Lymphoma
Lymphomas are a diverse group of hematologic malignancies that typically develops in lymph nodes and can originate from B cells, T cells, and natural killer cells. They are broadly divided into 2 categories, Hodgkin lymphoma and non-Hodgkin lymphoma.
Aggressive B-Cell Lymphoma
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Zilovertamab vedotin plus R-GemOx shows promise in R/R DLBCL, with RP2D set at 1.75 mg/kg per WaveLINE-003 phase 2/3 trial.
Dr. Frederick Locke discussed the ZUMA-7 trial of axi-cel versus standard of care for patients with relapsed/refractory LBCL.
Advertisement
Hodgkin Lymphoma
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
Should interim PET scans still guide Hodgkin lymphoma treatment? Experts debate imaging, SUV changes and biopsy use in HL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Checkpoint inhibitors show promise as second-line salvage therapy in advanced Hodgkin lymphoma, per Philippe Armand, MD, PhD
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Indolent B-Cell Lymphoma
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Charles Gaulin, MBBS, discussed the future of lymphoma treatment, including the development of novel cellular therapies.
Advertisement
Mantle Cell Lymphoma
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
Acalabrutinib plus bendamustine-rituximab is a new standard therapy for patients 65 years or older with untreated MCL.
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
T-Cell Lymphoma
Paola Ghione, MD, discusses these findings and how breast implant-associated anaplastic large cell lymphoma is managed.
11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT.
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
Experts discuss T-cell lymphoma care, new therapies, transplant timing, and the role of NGS in treatment decisions.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.